TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91687

Peptide_Name

HAL-2/8 HAL-2

Activity

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb APD_complete APD_hemolytic Hemolytic2 PD_Hemolysis ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 12-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

GKWMSLLKHILK-NH2

FASTA

>TPDB91687|Antibacterial;Anticancer;Antifungal;Antiparasitic;Antiviral;Hemolysis;Toxicity|length=12
GKWMSLLKHILK-NH2

Formula C69H116N18O14S1

Absent Amino Acids ARNDCEQFPTYV

Common Amino Acids LK

Mass 1453.85

PI 10.84

Basic Residues 4

Acidic Residues 0

Hydrophobic Residues 6

Net Charge +3

Boman Index -0.00

Hydrophobicity 0.067

Aliphatic Index 130.00

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 5500

Absorbance 280nm 378.31

Polar Residues 1

number

0

A

0

R

0

N

0

D

0

C

0

E

0

Q

1

G

1

H

1

I

3

L

3

K

1

M

0

F

0

P

1

S

0

T

1

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 1 L: 3 K: 3 M: 1 F: 0 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 0

Length

12

Formula

C69H116N18O14S1

Mass

1453.85

PI

10.84

Net Charge

+3

Boman Index

-0.00

Hydrophobicity

0.067

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial and Antifungal

Origin

Halictines and their analogs

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 12±1 µM

Detail Source Activity Anticancer

Activity Measurement 12

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 15±3 µM

Detail Source Activity Anticancer

Activity Measurement 15

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 35±3 µM

Detail Source Activity Anticancer

Activity Measurement 35

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 > 40 µM

Detail Source Activity Anticancer

Activity Measurement 40 µM

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 34 µM

Detail Source Activity Anticancer

Activity Measurement 34 µM

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 6 Activity

Activity

Activity Raw

Not tested

Detail Source Activity Anticancer

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012